Hospitals and providers are now seeing more patients with severe acute pain who are on chronic buprenorphine therapy, and these cases present challenges to pain control when treatment with a pure opioid is used.
MONTCLAIR, N.J. (PRWEB) October 23, 2018
PAINWeekEnd on November 17 at the Courtyard by Marriott Philadelphia Downtown, 21 N. Juniper Street in Pennsylvania, will be an educational and exciting program providing busy clinicians and allied healthcare practitioners with 6.0 hours of relevant, practical instruction in the management of chronic pain.
The Pennsylvania State Legislature is actively engaged in the issue of opioid abuse in the state, with 17 new bills introduced in the most recent legislative session. While physician groups including the Pennsylvania Medical Society have supported various measures to expand the state’s PDMP, create voluntary guidelines for prescribers, and expand physician education, they have also opposed recent proposals by the legislature to make prescribing guidelines mandatory, citing the need for patient-specific decisions made by individual clinicians. In light of this changing legislative and regulatory arena, the curriculum to be presented at PAINWeekEnd Philadelphia will equip participants with knowledge and skills to better negotiate the prescribing landscape while meeting the needs of their patients. Tanya Uritsky, PharmD, BCPS, commented on her course To Dream the Impossible Dream: Acute Pain Management for Patients on Buprenorphine, a review of the unique characteristics of buprenorphine and an outline of options for treating severe acute pain in patients already on buprenorphine therapy. “Buprenorphine, an important weapon in the arsenal for management of substance use disorder, is now rising in popularity as an opioid option for chronic pain,” Dr. Uritsky remarked. “Hospitals and providers are now seeing more patients with severe acute pain who are on chronic buprenorphine therapy, and these cases present challenges to pain control when treatment with a pure opioid is used.” Dr. Uritsky will also be presenting 3's Company: COX-2 Inhibitors, Medicinal Marijuana, and Opioid Prescribing.
Other course topics to be offered at PAINWeekEnd Philadelphia include Big News in Small Fiber Neuropathies; Evidence-Based Approaches to Chronic Pain Management: Time to Reconsider the Benefit of Technophilism; Lost in Translation: Making Sense of Clinical Treatment Guidelines; and Reefer Madness Revisited.
Commercially supported activities—addressing a range of product, disease state, and medical information topics—will also be presented.
For more information about this or other regional conferences, and to register for $129, go to the PAINWeekEnd website. BONUS: PAINWeekEnd registrants may register for the 2019 PAINWeek National Conference, September 3-7, in Las Vegas, for $200 off the regular online published price.
PAINWeekEnd is provided by Global Education Group. About Global Education Group:
Global Education Group focuses on producing partnership-based CME for healthcare practitioners. The Global team works with a select group of medical education companies, associations, academic institutions and healthcare facilities to develop and accredit live healthcare conferences and workshops as well as online activities. With each partnership or joint providership, Global brings accreditation expertise, project management excellence and grant funding intelligence. Based in Littleton, Colo., Global has accreditation with commendation from the ACCME. Global also holds accreditations to offer continuing education for nurses, nurse practitioners, pharmacists, dietitians, dentists and psychologists. Global is a division of Ultimate Medical Academy.